Pulmonary Hypertension

Seralutinib Phase 2 Circulating Biomarker Substudy in PAH

AJRCCM, 2026Phase 2 substudy (biomarker analysis from PROSERA / TORREY-related cohort)Source: Abstract not available — Letter / brief report formatDOI: 10.1093/ajrccm/aamag175PMID 42104009

Authors: Gossamer Bio + PAH centers (Boucly, Channick, Hemnes, McLaughlin, Sitbon, Ghofrani, et al.)
Journal / date: AJRCCM, 2026
DOI / URL: 10.1093/ajrccm/aamag175 | PMID 42104009
Source basis: Abstract not available — Letter / brief report format
Study type: Phase 2 substudy (biomarker analysis from PROSERA / TORREY-related cohort)
PH group: Group 1 (PAH)
Key context: Seralutinib is an inhaled PDGFRα/β + CSF1R + c-KIT tyrosine kinase inhibitor in development for PAH. The full clinical efficacy results have been reported previously; this substudy reports circulating biomarker changes with treatment.
Why it matters (clinical takeaway):

Track seralutinib closely — second novel mechanism (after sotatercept) reaching Phase 3 in PAH.
Biomarker substudies inform mechanism and patient selection; pending full data, this remains background reading.

Caveats / limitations: Full abstract not retrievable via PubMed; depends on full-text access through other channels. Sponsor-affiliated.
Referenced trials pulled forward: TORREY (seralutinib Phase 2 PAH) and PROSERA (Phase 3) — to add to trials/ on next pass.